Historique
Périodique
Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders
Auteur(s) :
WOOD, M. D.
Année
2003
Page(s) :
383-387
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Domaine :
Hors addiction / No addiction
Note générale :
Current Drug Targets - CNS and Neurological Disorders, 2003, 2, (6), 383-387
Résumé :
ENGLISH :
Anxiety disorders are the most common psychiatric illness affecting both adults and children. Following the observation that m-chlorophenylpiperazine(mCPP) induced anxiety-like states in patients and in animal models, it was shown that in man, mCPP behaves as a functionally selective agonist at the 5-hydroxytryptamine (5-HT)2C receptor. This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders. This review examines the pre-clinical and clinical evidence for a role of the 5-HT2C receptor in anxiety and evaluates the progress of compounds that target this therapeutic approach. (Author' s abstract)
Affiliation :
Psychiatry Centre of Excellence for Drug Discovery, Department of Biology, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW. Email: martyn.wood-1@gsk.com
Royaume-Uni. United Kingdom.
Royaume-Uni. United Kingdom.
Cote :
A01986